Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Massachusetts Delegation Alerts Shalala To Outpatient PPS Concerns

This article was originally published in The Gray Sheet

Executive Summary

A group of Massachusetts lawmakers is asking HHS Secretary Donna Shalala to provide retroactive payments for firms whose devices qualify for "pass through" or "new technology" payments under the outpatient prospective payment system but who missed the recent deadline for submission of applications.

You may also be interested in...



Non-Implantable Devices Are Eligible For OPPS New Technology List - DeParle

Cardiac catheters are among the non-implantable devices likely to be included in the Health Care Financing Administration's updated list of "new technology" items eligible for additional payments beginning July 1 under the hospital outpatient prospective payment system.

Outpatient PPS Final Rule Describes Criteria For "Pass-Through" Eligibility

Certain new technologies are not eligible for the "pass-through" provisions of the hospital outpatient prospective payment system if the cost to obtain the product is not "large enough relative to the fee schedule amount" to deter hospital purchases, the final rule implementing the outpatient PPS states.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT013338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel